36 results on '"Brand TM"'
Search Results
2. Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
- Author
-
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, and Grandis JR
- Published
- 2022
- Full Text
- View/download PDF
3. Retraction.
- Author
-
Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, and Wheeler DL
- Published
- 2021
- Full Text
- View/download PDF
4. Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV + Patients.
- Author
-
Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Wechsler EI, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, and Grandis JR
- Published
- 2021
- Full Text
- View/download PDF
5. Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer.
- Author
-
Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, and Wheeler DL
- Published
- 2019
- Full Text
- View/download PDF
6. Correction: Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.
- Author
-
Iida M, Brand TM, Campbell DA, Li C, and Wheeler DL
- Abstract
In Figure 4C, it was identified that the Histone H3 and α-Tubulin purification control blots for YES and LYN overexpressing cells were duplicated. The original Histone H3 control blot was found and confirmed the published results, however, the α-Tubulin control blot was not found. This error was determined to not impact the scientific findings of this figure. The authors regret this error.
- Published
- 2019
- Full Text
- View/download PDF
7. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA -altered head and neck cancer.
- Author
-
Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, and Grandis JR
- Subjects
- Adult, Aged, Animals, Disease-Free Survival, Female, Humans, Male, Mice, Mice, Inbred NOD, Middle Aged, Survival Rate, Xenograft Model Antitumor Assays, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Carcinoma, Squamous Cell enzymology, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell therapy, Class I Phosphatidylinositol 3-Kinases genetics, Class I Phosphatidylinositol 3-Kinases metabolism, Head and Neck Neoplasms enzymology, Head and Neck Neoplasms genetics, Head and Neck Neoplasms mortality, Head and Neck Neoplasms therapy, Mutation, Neoplasm Proteins genetics, Neoplasm Proteins metabolism
- Abstract
PIK3CA is the most commonly altered oncogene in head and neck squamous cell carcinoma (HNSCC). We evaluated the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on survival in a PIK3CA -characterized cohort of 266 HNSCC patients and explored the mechanism in relevant preclinical models including patient-derived xenografts. Among subjects with PIK3CA mutations or amplification, regular NSAID use (≥6 mo) conferred markedly prolonged disease-specific survival (DSS; hazard ratio 0.23, P = 0.0032, 95% CI 0.09-0.62) and overall survival (OS; hazard ratio 0.31, P = 0.0043, 95% CI 0.14-0.69) compared with nonregular NSAID users. For PIK3CA -altered HNSCC, predicted 5-yr DSS was 72% for NSAID users and 25% for nonusers; predicted 5-yr OS was 78% for regular NSAID users and 45% for nonregular users. PIK3CA mutation predicted sensitivity to NSAIDs in preclinical models in association with increased systemic PGE
2 production. These findings uncover a biologically plausible rationale to implement NSAID therapy in PIK3CA -altered HNSCC., (© 2019 Hedberg et al.)- Published
- 2019
- Full Text
- View/download PDF
8. Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77].
- Author
-
Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, and Wheeler DL
- Published
- 2019
- Full Text
- View/download PDF
9. Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
- Author
-
Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, and Wheeler DL
- Published
- 2018
- Full Text
- View/download PDF
10. Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network.
- Author
-
Eckhardt M, Zhang W, Gross AM, Von Dollen J, Johnson JR, Franks-Skiba KE, Swaney DL, Johnson TL, Jang GM, Shah PS, Brand TM, Archambault J, Kreisberg JF, Grandis JR, Ideker T, and Krogan NJ
- Subjects
- Biomarkers, Tumor genetics, Carcinogenesis metabolism, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell virology, Head and Neck Neoplasms metabolism, Head and Neck Neoplasms virology, Humans, Mutation, Papillomavirus Infections virology, Protein Interaction Maps, Biomarkers, Tumor metabolism, Carcinogenesis pathology, Carcinoma, Squamous Cell pathology, Head and Neck Neoplasms pathology, Host-Pathogen Interactions, Papillomaviridae physiology, Papillomavirus Infections complications
- Abstract
We have mapped a global network of virus-host protein interactions by purification of the complete set of human papillomavirus (HPV) proteins in multiple cell lines followed by mass spectrometry analysis. Integration of this map with tumor genome atlases shows that the virus targets human proteins frequently mutated in HPV
- but not HPV+ cancers, providing a unique opportunity to identify novel oncogenic events phenocopied by HPV infection. For example, we find that the NRF2 transcriptional pathway, which protects against oxidative stress, is activated by interaction of the NRF2 regulator KEAP1 with the viral protein E1. We also demonstrate that the L2 HPV protein physically interacts with the RNF20/40 histone ubiquitination complex and promotes tumor cell invasion in an RNF20/40-dependent manner. This combined proteomic and genetic approach provides a systematic means to study the cellular mechanisms hijacked by virally induced cancers. Significance: In this study, we created a protein-protein interaction network between HPV and human proteins. An integrative analysis of this network and 800 tumor mutation profiles identifies multiple oncogenesis pathways promoted by HPV interactions that phenocopy recurrent mutations in cancer, yielding an expanded definition of HPV oncogenic roles. Cancer Discov; 8(11); 1474-89. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333 ., (©2018 American Association for Cancer Research.)- Published
- 2018
- Full Text
- View/download PDF
11. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
- Author
-
Leonard B, Brand TM, O'Keefe RA, Lee ED, Zeng Y, Kemmer JD, Li H, Grandis JR, and Bhola NE
- Subjects
- Carcinoma, Squamous Cell genetics, Cell Line, Tumor, Cell Survival genetics, Head and Neck Neoplasms genetics, Humans, Receptor, ErbB-2 genetics, Signal Transduction genetics, Transcription Factors genetics, Cetuximab pharmacology, Drug Resistance, Neoplasm genetics, Nuclear Proteins genetics, Proteins genetics, Receptor Protein-Tyrosine Kinases genetics, Squamous Cell Carcinoma of Head and Neck drug therapy, Squamous Cell Carcinoma of Head and Neck genetics
- Abstract
Cetuximab, the FDA-approved anti-EGFR antibody for head and neck squamous cell carcinoma (HNSCC), has displayed limited efficacy due to the emergence of intrinsic and acquired resistance. We and others have demonstrated that cetuximab resistance in HNSCC is driven by alternative receptor tyrosine kinases (RTK), including HER3, MET, and AXL. In an effort to overcome cetuximab resistance and circumvent toxicities associated with the administration of multiple RTK inhibitors, we sought to identify a common molecular target that regulates expression of multiple RTK. Bromodomain-containing protein-4 (BRD4) has been shown to regulate the transcription of various RTK in the context of resistance to PI3K and HER2 inhibition in breast cancer models. We hypothesized that, in HNSCC, targeting BRD4 could overcome cetuximab resistance by depleting alternative RTK expression. We generated independent models of cetuximab resistance in HNSCC cell lines and interrogated their RTK and BRD4 expression profiles. Cetuximab-resistant clones displayed increased expression and activation of several RTK, such as MET and AXL, as well as an increased percentage of BRD4-expressing cells. Both genetic and pharmacologic inhibition of BRD4 abrogated cell viability in models of acquired and intrinsic cetuximab resistance and was associated with a robust decrease in alternative RTK expression by cetuximab. Combined treatment with cetuximab and bromodomain inhibitor JQ1 significantly delayed acquired resistance and RTK upregulation in patient-derived xenograft models of HNSCC. These findings indicate that the combination of cetuximab and bromodomain inhibition may be a promising therapeutic strategy for patients with HNSCC. Significance: Inhibition of bromodomain protein BRD4 represents a potential therapeutic strategy to circumvent the toxicities and financial burden of targeting the multiple receptor tyrosine kinases that drive cetuximab resistance in HNSCC and NSCLC. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/15/4331/F1.large.jpg Cancer Res; 78(15); 4331-43. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
12. Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
- Author
-
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, and Grandis JR
- Subjects
- Animals, Antineoplastic Agents pharmacology, Cell Line, Tumor, Disease Models, Animal, Gene Knockdown Techniques, Head and Neck Neoplasms pathology, Humans, Phosphoinositide-3 Kinase Inhibitors, Protein Binding, Xenograft Model Antitumor Assays, Head and Neck Neoplasms etiology, Head and Neck Neoplasms metabolism, Oncogene Proteins, Viral metabolism, Papillomavirus E7 Proteins metabolism, Phosphatidylinositol 3-Kinases metabolism, Receptor, ErbB-3 metabolism, Repressor Proteins metabolism, Signal Transduction drug effects
- Abstract
Human papillomavirus (HPV) type 16 is implicated in approximately 75% of head and neck squamous cell carcinomas (HNSCC) that arise in the oropharynx, where viral expression of the E6 and E7 oncoproteins promote cellular transformation, tumor growth, and maintenance. An important oncogenic signaling pathway activated by E6 and E7 is the PI3K pathway, a key driver of carcinogenesis. The PI3K pathway is also activated by mutation or amplification of PIK3CA in over half of HPV(+) HNSCC. In this study, we investigated the efficacy of PI3K-targeted therapies in HPV(+) HNSCC preclinical models and report that HPV(+) cell line- and patient-derived xenografts are resistant to PI3K inhibitors due to feedback signaling emanating from E6 and E7. Receptor tyrosine kinase profiling indicated that PI3K inhibition led to elevated expression of the HER3 receptor, which in turn increased the abundance of E6 and E7 to promote PI3K inhibitor resistance. Targeting HER3 with siRNA or the mAb CDX-3379 reduced E6 and E7 abundance and enhanced the efficacy of PI3K-targeted therapies. Together, these findings suggest that cross-talk between HER3 and HPV oncoproteins promotes resistance to PI3K inhibitors and that cotargeting HER3 and PI3K may be an effective therapeutic strategy in HPV(+) tumors. Significance: These findings suggest a new therapeutic combination that may improve outcomes in HPV(+) head and neck cancer patients. Cancer Res; 78(9); 2383-95. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
13. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV + Patients.
- Author
-
Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, and Grandis JR
- Subjects
- Animals, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell virology, Cell Line, Tumor, Elafin genetics, Gene Expression Regulation, Neoplastic genetics, Gene Expression Regulation, Viral genetics, Head and Neck Neoplasms genetics, Head and Neck Neoplasms pathology, Head and Neck Neoplasms virology, Human papillomavirus 16 pathogenicity, Humans, Mice, Oncogene Proteins, Viral genetics, Papillomavirus E7 Proteins genetics, Papillomavirus Infections virology, RNA, Small Interfering administration & dosage, RNA, Small Interfering genetics, Receptor, ErbB-3 antagonists & inhibitors, Repressor Proteins genetics, Squamous Cell Carcinoma of Head and Neck, Xenograft Model Antitumor Assays, Carcinoma, Squamous Cell drug therapy, Head and Neck Neoplasms drug therapy, Molecular Targeted Therapy, Papillomavirus Infections genetics, Receptor, ErbB-3 genetics
- Abstract
Purpose: Human papillomavirus (HPV) 16 plays an etiologic role in a growing subset of head and neck squamous cell carcinomas (HNSCC), where viral expression of the E6 and E7 oncoproteins is necessary for tumor growth and maintenance. Although patients with HPV
+ tumors have a more favorable prognosis, there are currently no HPV-selective therapies. Recent studies identified differential receptor tyrosine kinase (RTK) profiles in HPV+ versus HPV- tumors. One such RTK, HER3, is overexpressed and interacts with phosphoinositide-3-kinase (PI3K) in HPV+ tumors. Therefore, we investigated the role of HPV oncoproteins in regulating HER3-mediated signaling and determined whether HER3 could be a molecular target in HPV+ HNSCC. Experimental Design: HER3 was investigated as a molecular target in HPV+ HNSCC using established cell lines, patient-derived xenografts (PDX), and human tumor specimens. A mechanistic link between HPV and HER3 was examined by augmenting E6 and E7 expression levels in HNSCC cell lines. The dependency of HPV+ and HPV- HNSCC models on HER3 was evaluated with anti-HER3 siRNAs and the clinical stage anti-HER3 monoclonal antibody KTN3379. Results: HER3 was overexpressed in HPV+ HNSCC, where it was associated with worse overall survival in patients with pharyngeal cancer. Further investigation indicated that E6 and E7 regulated HER3 protein expression and downstream PI3K pathway signaling. Targeting HER3 with siRNAs or KTN3379 significantly inhibited the growth of HPV+ cell lines and PDXs. Conclusions: This study uncovers a direct relationship between HPV infection and HER3 in HNSCC and provides a rationale for the clinical evaluation of targeted HER3 therapy for the treatment of HPV+ patients. Clin Cancer Res; 23(12); 3072-83. ©2016 AACR ., (©2016 American Association for Cancer Research.)- Published
- 2017
- Full Text
- View/download PDF
14. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
- Author
-
Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, and Wheeler DL
- Subjects
- Active Transport, Cell Nucleus, Animals, Antineoplastic Agents pharmacology, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Cell Line, Tumor, Cetuximab pharmacology, Drug Resistance, Neoplasm, ErbB Receptors genetics, Humans, Immunoblotting, Lung Neoplasms genetics, Lung Neoplasms pathology, Mice, Inbred NOD, Mice, SCID, Microscopy, Confocal, Neuregulin-1 genetics, Neuregulin-1 metabolism, Proto-Oncogene Proteins genetics, RNA Interference, Receptor Protein-Tyrosine Kinases genetics, Transplantation, Heterologous, src-Family Kinases genetics, src-Family Kinases metabolism, Axl Receptor Tyrosine Kinase, Carcinoma, Non-Small-Cell Lung metabolism, Cell Nucleus metabolism, ErbB Receptors metabolism, Lung Neoplasms metabolism, Proto-Oncogene Proteins metabolism, Receptor Protein-Tyrosine Kinases metabolism
- Abstract
The epidermal growth factor receptor (EGFR) is a therapeutic target in patients with various cancers. Unfortunately, resistance to EGFR-targeted therapeutics is common. Previous studies identified two mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Nuclear translocation of EGFR bypasses the inhibitory effects of cetuximab, and the receptor tyrosine kinase AXL mediates cetuximab resistance by maintaining EGFR activation and downstream signaling. Thus, we hypothesized that AXL mediated the nuclear translocation of EGFR in the setting of cetuximab resistance. Cetuximab-resistant clones of non-small cell lung cancer in culture and patient-derived xenografts in mice had increased abundance of AXL and nuclear EGFR (nEGFR). Cellular fractionation analysis, super-resolution microscopy, and electron microscopy revealed that genetic loss of AXL reduced the accumulation of nEGFR. SRC family kinases (SFKs) and HER family ligands promote the nuclear translocation of EGFR. We found that AXL knockdown reduced the expression of the genes encoding the SFK family members YES and LYN and the ligand neuregulin-1 (NRG1). AXL knockdown also decreased the interaction between EGFR and the related receptor HER3 and accumulation of HER3 in the nucleus. Overexpression of LYN and NRG1 in cells depleted of AXL resulted in accumulation of nEGFR, rescuing the deficit induced by lack of AXL. Collectively, these data uncover a previously unrecognized role for AXL in regulating the nuclear translocation of EGFR and suggest that AXL-mediated SFK and NRG1 expression promote this process., (Copyright © 2017, American Association for the Advancement of Science.)
- Published
- 2017
- Full Text
- View/download PDF
15. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
- Author
-
Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, and Wheeler DL
- Subjects
- Animals, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cell Cycle Checkpoints drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Disease Models, Animal, Female, Head and Neck Neoplasms, Humans, Male, Mice, Protein Kinase Inhibitors pharmacology, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-3 antagonists & inhibitors, Squamous Cell Carcinoma of Head and Neck, Tumor Burden, Xenograft Model Antitumor Assays, Antibodies, Monoclonal pharmacology, Antineoplastic Agents pharmacology, Cetuximab pharmacology, Drug Resistance, Neoplasm, ErbB Receptors antagonists & inhibitors
- Abstract
Cetuximab, an antibody against the EGFR, has shown efficacy in treating head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer, and non-small cell lung cancer (NSCLC). Despite the clinical success of cetuximab, many patients do not respond to cetuximab. Furthermore, virtually all patients who do initially respond become refractory, highlighting both intrinsic and acquired resistance to cetuximab as significant clinical problems. To understand mechanistically how cancerous cells acquire resistance, we previously developed models of acquired resistance using the H226 NSCLC and UM-SCC1 HNSCC cell lines. Cetuximab-resistant clones showed a robust upregulation and dependency on the HER family receptors EGFR, HER2, and HER3. Here, we examined pan-HER, a mixture of six antibodies targeting these receptors on cetuximab-resistant clones. In cells exhibiting acquired or intrinsic resistance to cetuximab, pan-HER treatment decreased all three receptors' protein levels and downstream activation of AKT and MAPK. This correlated with decreased cell proliferation in cetuximab-resistant clones. To determine whether pan-HER had a therapeutic benefit in vivo, we established de novo cetuximab-resistant mouse xenografts and treated resistant tumors with pan-HER. This regimen resulted in a superior growth delay of cetuximab-resistant xenografts compared with mice continued on cetuximab. Furthermore, intrinsically cetuximab-resistant HNSCC patient-derived xenograft tumors treated with pan-HER exhibited significant growth delay compared with vehicle/cetuximab controls. These results suggest that targeting multiple HER family receptors simultaneously with pan-HER is a promising treatment strategy for tumors displaying intrinsic or acquired resistance to cetuximab. Mol Cancer Ther; 15(9); 2175-86. ©2016 AACR., Competing Interests: of Potential Conflicts of Interest: D.L. Wheeler holds a laboratory research agreement with Symphogen A/S. J. Lantto, I.D. Horak, and M. Kragh are employed by Symphogen A/S. No potential conflicts of interest were disclosed by other authors., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
16. Adaptive responses to antibody based therapy.
- Author
-
Rodems TS, Iida M, Brand TM, Pearson HE, Orbuch RA, Flanigan BG, and Wheeler DL
- Subjects
- Animals, ErbB Receptors metabolism, Humans, Molecular Targeted Therapy, Neoplasms drug therapy, Neoplasms metabolism, Receptor Protein-Tyrosine Kinases metabolism, Receptor, ErbB-2 metabolism, Adaptation, Physiological, Antibodies therapeutic use
- Abstract
Receptor tyrosine kinases (RTKs) represent a large class of protein kinases that span the cellular membrane. There are 58 human RTKs identified which are grouped into 20 distinct families based upon their ligand binding, sequence homology and structure. They are controlled by ligand binding which activates intrinsic tyrosine-kinase activity. This activity leads to the phosphorylation of distinct tyrosines on the cytoplasmic tail, leading to the activation of cell signaling cascades. These signaling cascades ultimately regulate cellular proliferation, apoptosis, migration, survival and homeostasis of the cell. The vast majority of RTKs have been directly tied to the etiology and progression of cancer. Thus, using antibodies to target RTKs as a cancer therapeutic strategy has been intensely pursued. Although antibodies against the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) have shown promise in the clinical arena, the development of both intrinsic and acquired resistance to antibody-based therapies is now well appreciated. In this review we provide an overview of the RTK family, the biology of EGFR and HER2, as well as an in-depth review of the adaptive responses undertaken by cells in response to antibody based therapies directed against these receptors. A greater understanding of these mechanisms and their relevance in human models will lead to molecular insights in overcoming and circumventing resistance to antibody based therapy., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
17. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
- Author
-
Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, and Wheeler DL
- Subjects
- Animals, Benzocycloheptenes administration & dosage, Carcinoma, Squamous Cell pathology, Cell Line, Tumor, Drug Resistance, Neoplasm genetics, Gene Expression Regulation, Neoplastic drug effects, Head and Neck Neoplasms pathology, Humans, Mice, Proto-Oncogene Proteins antagonists & inhibitors, Proto-Oncogene Proteins genetics, RNA, Small Interfering genetics, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Receptor Protein-Tyrosine Kinases genetics, Squamous Cell Carcinoma of Head and Neck, Triazoles administration & dosage, Xenograft Model Antitumor Assays, Axl Receptor Tyrosine Kinase, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell genetics, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms genetics, Molecular Targeted Therapy, Proto-Oncogene Proteins biosynthesis, Receptor Protein-Tyrosine Kinases biosynthesis
- Abstract
Purpose: Head and neck squamous cell carcinoma (HNSCC) represents the eighth most common malignancy worldwide. Standard-of-care treatments for patients with HNSCC include surgery, radiation, and chemotherapy. In addition, the anti-EGFR monoclonal antibody cetuximab is often used in combination with these treatment modalities. Despite clinical success with these therapeutics, HNSCC remains a difficult malignancy to treat. Thus, identification of new molecular targets is critical., Experimental Design: In the current study, the receptor tyrosine kinase AXL was investigated as a molecular target in HNSCC using established cell lines, HNSCC patient-derived xenografts (PDX), and human tumors. HNSCC dependency on AXL was evaluated with both anti-AXL siRNAs and the small-molecule AXL inhibitor R428. Furthermore, AXL inhibition was evaluated with standard-of-care treatment regimens used in HNSCC., Results: AXL was found to be highly overexpressed in several models of HNSCC, where AXL was significantly associated with higher pathologic grade, presence of distant metastases, and shorter relapse-free survival in patients with HNSCC. Further investigations indicated that HNSCC cells were reliant on AXL for cellular proliferation, migration, and invasion. In addition, targeting AXL increased HNSCC cell line sensitivity to chemotherapy, cetuximab, and radiation. Moreover, radiation-resistant HNSCC cell line xenografts and PDXs expressed elevated levels of both total and activated AXL, indicating a role for AXL in radiation resistance., Conclusions: This study provides evidence for the role of AXL in HNSCC pathogenesis and supports further preclinical and clinical evaluation of anti-AXL therapeutics for the treatment of patients with HNSCC., (©2015 American Association for Cancer Research.)
- Published
- 2015
- Full Text
- View/download PDF
18. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
- Author
-
Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, and Wheeler DL
- Subjects
- Animals, Antibodies, Neutralizing, Antineoplastic Agents therapeutic use, Broadly Neutralizing Antibodies, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Cetuximab, ErbB Receptors metabolism, Humans, Lung Neoplasms drug therapy, Lung Neoplasms metabolism, Male, Mice, Mice, Nude, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism, Receptor, ErbB-2 metabolism, Signal Transduction drug effects, Xenograft Model Antitumor Assays methods, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Drug Resistance, Neoplasm drug effects, Receptor, ErbB-3 metabolism
- Abstract
Background: Cetuximab, an anti-EGFR monoclonal antibody, is used to treat several cancers. However, many patients who initially respond to cetuximab acquire resistance. To examine mechanisms of acquired resistance, we developed a series of cetuximab-resistant (Ctx(R)) clones derived from the cetuximab sensitive (CtxS) non-small cell lung cancer (NSCLC) cell line H226. Previous studies characterizing this model revealed that: 1) EGFR was robustly overexpressed in Ctx(R) clones due to decreased EGFR ubiquitination and degradation and 2) Ctx(R) clones expressed increased HER2 and HER3 activation resulting in constitutive activation of the PI3K/AKT signaling axis. These findings suggest that dual targeting HER family receptors would be highly beneficial in the Ctx(R) setting., Results: Since HER3 has been implicated in resistance to EGFR inhibitors, the efficacy of dually targeting both EGFR and HER3 in Ctx(R) models was evaluated. First, EGFR and HER3 expression were knocked down with siRNAs. Compared to the Ctx(S) parental cell line (HP), all Ctx(R) clones exhibited robust decreases in cell proliferation upon dual knockdown. Analysis of Ctx(R) clones indicated that neuregulin-1 was highly overexpressed compared to HP cells. Incubation of HP cells with neuregulin-1 rendered them resistant to cetuximab. Next, dual treatment of Ctx(R) clones with cetuximab and the HER3 neutralizing monoclonal antibody (mAb) U3-1287 led to potent anti-proliferative effects. Blockade of EGFR with cetuximab resulted in inactivation of MAPK, while blockade of HER3 with U3-1287 resulted in the inactivation of AKT. Treatment with both mAbs resulted in knockdown of both signaling pathways simultaneously. HER2 was also strongly inactivated upon dual mAb therapy, suggesting that this treatment regimen can diminish signaling from three HER family receptors. De novo CtxR H226 mouse xenografts were established to determine if dual therapy could overcome acquired resistance to cetuximab in vivo. Tumors that had acquired resistance to cetuximab were significantly growth delayed upon dual treatment of U3-1287 and cetuximab compared to those continued on cetuximab only. Combinatorial-treated xenograft tumors expressed decreased Ki67 and increased cleaved caspase-3 levels compared to tumors treated with either monotherapy., Conclusions: These studies demonstrate that dually targeting HER family receptors with antibody-based therapies can overcome acquired resistance to cetuximab.
- Published
- 2014
- Full Text
- View/download PDF
19. AXL mediates resistance to cetuximab therapy.
- Author
-
Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, and Wheeler DL
- Subjects
- Animals, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell pathology, Cell Growth Processes drug effects, Cell Line, Tumor, Cetuximab, Drug Resistance, Neoplasm, Head and Neck Neoplasms genetics, Head and Neck Neoplasms pathology, Humans, Lung Neoplasms pathology, Mice, Mice, Nude, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, RNA, Small Interfering administration & dosage, RNA, Small Interfering genetics, Receptor Protein-Tyrosine Kinases genetics, Receptor Protein-Tyrosine Kinases metabolism, Squamous Cell Carcinoma of Head and Neck, Transfection, Xenograft Model Antitumor Assays, Axl Receptor Tyrosine Kinase, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents pharmacology, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung enzymology, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell enzymology, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms enzymology, Proto-Oncogene Proteins biosynthesis, Receptor Protein-Tyrosine Kinases biosynthesis
- Abstract
The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clinical outcome. In this study, we show that overexpression of the oncogenic receptor tyrosine kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), where AXL was overexpressed, activated, and tightly associated with EGFR expression in cells resistant to cetuximab (Ctx(R) cells). Using RNAi methods and novel AXL-targeting agents, we found that AXL activation stimulated cell proliferation, EGFR activation, and MAPK signaling in Ctx(R) cells. Notably, EGFR directly regulated the expression of AXL mRNA through MAPK signaling and the transcription factor c-Jun in Ctx(R) cells, creating a positive feedback loop that maintained EGFR activation by AXL. Cetuximab-sensitive parental cells were rendered resistant to cetuximab by stable overexpression of AXL or stimulation with EGFR ligands, the latter of which increased AXL activity and association with the EGFR. In tumor xenograft models, the development of resistance following prolonged treatment with cetuximab was associated with AXL hyperactivation and EGFR association. Furthermore, in an examination of patient-derived xenografts established from surgically resected HNSCCs, AXL was overexpressed and activated in tumors that displayed intrinsic resistance to cetuximab. Collectively, our results identify AXL as a key mediator of cetuximab resistance, providing a rationale for clinical evaluation of AXL-targeting drugs to treat cetuximab-resistant cancers. Cancer Res; 74(18); 5152-64. ©2014 AACR., (©2014 American Association for Cancer Research.)
- Published
- 2014
- Full Text
- View/download PDF
20. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
- Author
-
Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, and Wheeler DL
- Subjects
- Animals, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents pharmacology, Cell Line, Tumor, Cell Proliferation, Cetuximab, Disease Models, Animal, Drug Resistance, Neoplasm genetics, ErbB Receptors antagonists & inhibitors, ErbB Receptors genetics, Female, Gene Expression, Humans, Mice, Protein Transport, Signal Transduction drug effects, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms pathology, Xenograft Model Antitumor Assays, src-Family Kinases metabolism, Cell Nucleus metabolism, ErbB Receptors metabolism, Triple Negative Breast Neoplasms metabolism
- Abstract
Triple-negative breast cancer (TNBC) is a subclass of breast cancers (i.e., estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) that have poor prognosis and very few identified molecular targets. Strikingly, a high percentage of TNBCs overexpresses the EGF receptor (EGFR), yet EGFR inhibition has yielded little clinical benefit. Over the last decade, advances in EGFR biology have established that EGFR functions in two distinct signaling pathways: (i) classical membrane-bound signaling and (ii) nuclear signaling. Previous studies have demonstrated that nuclear EGFR (nEGFR) can enhance resistance to anti-EGFR therapies and is correlated with poor overall survival in breast cancer. On the basis of these findings, we hypothesized that nEGFR may promote intrinsic resistance to cetuximab in TNBC. To examine this question, a battery of TNBC cell lines and human tumors were screened and found to express nEGFR. Knockdown of EGFR expression demonstrated that TNBC cell lines retained dependency on EGFR for proliferation, yet all cell lines were resistant to cetuximab. Furthermore, Src Family Kinases (SFKs) influenced nEGFR translocation in TNBC cell lines and in vivo tumor models, where inhibition of SFK activity led to potent reductions in nEGFR expression. Inhibition of nEGFR translocation led to a subsequent accumulation of EGFR on the plasma membrane, which greatly enhanced sensitivity of TNBC cells to cetuximab. Collectively, these data suggest that targeting both the nEGFR signaling pathway, through the inhibition of its nuclear transport, and the classical EGFR signaling pathway with cetuximab may be a viable approach for the treatment of patients with TNBC.
- Published
- 2014
- Full Text
- View/download PDF
21. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
- Author
-
Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, and Salgia R
- Subjects
- Camptothecin administration & dosage, Camptothecin analogs & derivatives, Carcinoma, Small Cell genetics, Carcinoma, Small Cell pathology, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Gene Dosage genetics, Gene Expression Regulation, Neoplastic drug effects, Humans, Indoles administration & dosage, Irinotecan, Middle Aged, Piperazines administration & dosage, Proto-Oncogene Proteins c-met antagonists & inhibitors, Signal Transduction drug effects, Small Cell Lung Carcinoma genetics, Small Cell Lung Carcinoma pathology, Sulfonamides administration & dosage, Topoisomerase I Inhibitors administration & dosage, Carcinoma, Small Cell drug therapy, DNA Topoisomerases, Type I genetics, Proto-Oncogene Proteins c-met genetics, Small Cell Lung Carcinoma drug therapy
- Abstract
Small cell lung cancer (SCLC) is a devastating disease, and current therapies have not greatly improved the 5-year survival rates. Topoisomerase (Top) inhibition is a treatment modality for SCLC; however, the response is short lived. Consequently, our research has focused on improving SCLC therapeutics through the identification of novel targets. Previously, we identified MNNG HOS transforming gene (MET) to be overexpressed and functional in SCLC. Herein, we investigated the therapeutic potential of combinatorial targeting of MET using SU11274 and Top1 using 7-ethyl-10-hydroxycamptothecin (SN-38). MET and TOP1 gene copy numbers and protein expression were determined in 29 patients with limited (n = 11) and extensive (n = 18) disease. MET gene copy number was significantly increased (>6 copies) in extensive disease compared with limited disease (P = 0.015). Similar TOP1 gene copy numbers were detected in limited and extensive disease. Immunohistochemical staining revealed a significantly higher Top1 nuclear expression in extensive (0.93) versus limited (0.15) disease (P = 0.04). Interestingly, a significant positive correlation was detected between MET gene copy number and Top1 nuclear expression (r = 0.5). In vitro stimulation of H82 cells revealed hepatocyte growth factor (HGF)-induced nuclear colocalization of p-MET and Top1. Furthermore, activation of the HGF/MET axis enhanced Top1 activity, which was abrogated by SU11274. Combination of SN-38 with SU11274 dramatically decreased SCLC growth as compared with either drug alone. Collectively, these findings suggest that the combinatorial inhibition of MET and Top1 is a potentially efficacious treatment strategy for SCLC., (©2013 AACR.)
- Published
- 2014
- Full Text
- View/download PDF
22. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
- Author
-
Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, and Wheeler DL
- Subjects
- Animals, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Cell Line, Tumor, Cell Proliferation drug effects, Cetuximab, ErbB Receptors metabolism, Heterografts, Humans, MAP Kinase Signaling System, Male, Mice, Mice, Nude, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents pharmacology, Drug Resistance, Neoplasm drug effects, ErbB Receptors immunology
- Abstract
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for head and neck and colorectal cancer treatment, but many patients treated with cetuximab don't respond or eventually acquire resistance. To determine how tumor cells acquire resistance to cetuximab, we previously developed a model of acquired resistance using the non-small cell lung cancer line NCI-H226. These cetuximab-resistant (Ctx(R)) cells exhibit increased steady-state EGFR expression secondary to alterations in EGFR trafficking and degradation and, further, retained dependence on EGFR signaling for enhanced growth potential. Here, we examined Sym004, a novel mixture of antibodies directed against distinct epitopes on the extracellular domain of EGFR, as an alternative therapy for Ctx(R) tumor cells. Sym004 treatment of Ctx(R) clones resulted in rapid EGFR degradation, followed by robust inhibition of cell proliferation and down-regulation of several mitogen-activated protein kinase pathways. To determine whether Sym004 could have therapeutic benefit in vivo, we established de novo Ctx(R) NCI-H226 mouse xenografts and subsequently treated Ctx(R) tumors with Sym004. Sym004 treatment of mice harboring Ctx(R) tumors resulted in growth delay compared to mice continued on cetuximab. Levels of total and phospho-EGFR were robustly decreased in Ctx(R) tumors treated with Sym004. Immunohistochemical analysis of these Sym004-treated xenograft tumors further demonstrated decreased expression of Ki67, and phospho-rpS6, as well as a modest increase in cleaved caspase-3. These results indicate that Sym004 may be an effective targeted therapy for Ctx(R) tumors.
- Published
- 2013
- Full Text
- View/download PDF
23. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.
- Author
-
Li C, Brand TM, Iida M, Huang S, Armstrong EA, van der Kogel A, and Wheeler DL
- Subjects
- Animals, Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Broadly Neutralizing Antibodies, Cell Death drug effects, Cell Death genetics, Cell Line, Tumor, Cell Survival drug effects, Cell Survival genetics, DNA Damage, Enzyme Induction drug effects, Enzyme Induction genetics, Gene Expression Regulation, Neoplastic drug effects, Gene Expression Regulation, Neoplastic genetics, Head and Neck Neoplasms enzymology, Head and Neck Neoplasms genetics, Head and Neck Neoplasms pathology, Heterografts, Humans, Lung Neoplasms enzymology, Lung Neoplasms genetics, Lung Neoplasms pathology, Male, Mice, Mice, Nude, Neoplasm Transplantation, Receptor, ErbB-3 antagonists & inhibitors, Receptor, ErbB-3 genetics, Antibodies, Monoclonal pharmacology, Antibodies, Neoplasm pharmacology, Head and Neck Neoplasms therapy, Lung Neoplasms therapy, Receptor, ErbB-3 biosynthesis
- Abstract
HER3 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. In the present study, we investigated the capacity of the HER3 blocking antibody, U3-1287/AMG888, to modulate the in vitro and in vivo radiation response of human squamous cell carcinomas of the lung and head and neck. We screened a battery of cell lines from these tumors for HER3 expression and demonstrated that all cell lines screened exhibited expression of HER3. Importantly, U3-1287/AMG888 treatment could block both basal HER3 activity and radiation induced HER3 activation. Proliferation assays indicated that HER3 blockade could decrease the proliferation of both HNSCC cell line SCC6 and NSCLC cell line H226. Further, we demonstrated that U3-1287/AMG888 can sensitize cells to radiation in clonogenic survival assays, in addition to increasing DNA damage as detected via λ-H2AX immunofluorescence. To determine if U3-1287/AMG888 could enhance radiation sensitivity in vivo we performed tumor growth delay experiments using SCC6, SCC1483, and H226 xenografts. The results of these experiments indicated that the combination of U3-1287/AMG888 and radiation could decrease tumor growth in studies using single or fractionated doses of radiation. Analysis of HER3 expression in tumor samples indicated that radiation treatment activated HER3 in vivo and that U3-1287/AMG888 could abrogate this activation. Immunohistochemistry analysis of SCC6 tumors treated with both U3-1287/AMG888 and a single dose of radiation demonstrated that various cell survival and proliferation markers could be reduced. Collectively our findings suggest that U3-1287/AMG888 in combination with radiation has an impact on cell and tumor growth by increasing DNA damage and cell death. These findings suggest that HER3 may play an important role in response to radiation therapy and blocking its activity in combination with radiation may be of therapeutic benefit in human tumors.
- Published
- 2013
24. Nuclear EGFR as a molecular target in cancer.
- Author
-
Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, and Wheeler DL
- Subjects
- Animals, Celecoxib, Cell Line, Tumor, Drug Resistance, Neoplasm, ErbB Receptors physiology, Humans, Proliferating Cell Nuclear Antigen physiology, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Pyrazoles pharmacology, Radiation Tolerance, Sulfonamides pharmacology, ErbB Receptors antagonists & inhibitors, Neoplasms drug therapy
- Abstract
The epidermal growth factor receptor (EGFR) has been one of the most targeted receptors in the field of oncology. While anti-EGFR inhibitors have demonstrated clinical success in specific cancers, most patients demonstrate either intrinsic or acquired resistance within one year of treatment. Many mechanisms of resistance to EGFR inhibitors have been identified, one of these being attributed to alternatively localized EGFR from the cell membrane into the cell's nucleus. Inside the nucleus, EGFR functions as a co-transcription factor for several genes involved in cell proliferation and angiogenesis, and as a tyrosine kinase to activate and stabilize proliferating cell nuclear antigen and DNA dependent protein kinase. Nuclear localized EGFR is highly associated with disease progression, worse overall survival in numerous cancers, and enhanced resistance to radiation, chemotherapy, and the anti-EGFR therapies gefitinib and cetuximab. In this review the current knowledge of how nuclear EGFR enhances resistance to cancer therapeutics is discussed, in addition to highlighting ways to target nuclear EGFR as an anti-cancer strategy in the future., (Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
25. Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.
- Author
-
Brand TM, Iida M, Luthar N, Wleklinski MJ, Starr MM, and Wheeler DL
- Subjects
- Cell Line, Cell Nucleus ultrastructure, Cyclin D1 analysis, Cyclin D1 genetics, Humans, Mutation, Promoter Regions, Genetic, Protein Structure, Tertiary, Receptor, ErbB-3 analysis, Receptor, ErbB-3 metabolism, Transcriptional Activation
- Abstract
Nuclear localized HER family receptor tyrosine kinases (RTKs) have been observed in primary tumor specimens and cancer cell lines for nearly two decades. Inside the nucleus, HER family members (EGFR, HER2, and HER3) have been shown to function as co-transcriptional activators for various cancer-promoting genes. However, the regions of each receptor that confer transcriptional potential remain poorly defined. The current study aimed to map the putative transactivation domains (TADs) of the HER3 receptor. To accomplish this goal, various intracellular regions of HER3 were fused to the DNA binding domain of the yeast transcription factor Gal4 (Gal4DBD) and tested for their ability to transactivate Gal4 UAS-luciferase. Results from these analyses demonstrated that the C-terminal domain of HER3 (CTD, amino acids distal to the tyrosine kinase domain) contained potent transactivation potential. Next, nine HER3-CTD truncation mutants were constructed to map minimal regions of transactivation potential using the Gal4 UAS-luciferase based system. These analyses identified a bipartite region of 34 (B₁) and 27 (B₂) amino acids in length that conferred the majority of HER3's transactivation potential. Next, we identified full-length nuclear HER3 association and regulation of a 122 bp region of the cyclin D1 promoter. To understand how the B₁ and B₂ regions influenced the transcriptional functions of nuclear HER3, we performed cyclin D1 promoter-luciferase assays in which HER3 deleted of the B₁ and B₂ regions was severely hindered in regulating this promoter. Further, the overexpression of HER3 enhanced cyclin D1 mRNA expression, while HER3 deleted of its identified TADs was hindered at doing so. Thus, the ability for HER3 to function as a transcriptional co-activator may be dependent on specific C-terminal TADs.
- Published
- 2013
- Full Text
- View/download PDF
26. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.
- Author
-
Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, Wheeler DL, Husain AN, Natarajan V, Vokes EE, Singleton PA, and Salgia R
- Subjects
- Focal Adhesions metabolism, HEK293 Cells, Humans, Lung Neoplasms metabolism, Mutation, Paxillin metabolism, Focal Adhesions genetics, Lung Neoplasms genetics, Mitochondrial Dynamics genetics, Paxillin genetics
- Abstract
Cytoskeletal and focal adhesion abnormalities are observed in several types of cancer, including lung cancer. We have previously reported that paxillin (PXN) was mutated, amplified, and overexpressed in a significant number of lung cancer patient samples, that PXN protein was upregulated in more advanced stages of lung cancer compared with lower stages, and that the PXN gene was also amplified in some pre-neoplastic lung lesions. Among the mutations investigated, we previously found that PXN variant A127T in lung cancer cells enhanced cell proliferation and focal adhesion formation and colocalized with the anti-apoptotic protein B Cell Lymphoma 2 (BCL-2), which is known to localize to the mitochondria, among other sites. To further explore the effects of activating mutations of PXN on mitochondrial function, we cloned and expressed wild-type PXN and variants containing the most commonly occurring PXN mutations (P46S, P52L, G105D, A127T, P233L, T255I, D399N, E423K, P487L, and K506R) in a GFP-tagged vector using HEK-293 human embryonic kidney cells. Utilizing live-cell imaging to systematically study the effects of wild-type PXN vs. mutants, we created a model that recapitulates the salient features of the measured dynamics and conclude that compared with wild-type, some mutant clones confer enhanced focal adhesion and lamellipodia formation (A127T, P233L, and P487L) and some confer increased association with BCL-2, Dynamin-related Protein-1 (DRP-1), and Mitofusion-2 (MFN-2) proteins (P233L and D399N). Further, PXN mutants, through their interactions with BCL-2 and DRP-1, could regulate cisplatin drug resistance in human lung cancer cells. The data reported herein suggest that mutant PXN variants play a prominent role in mitochondrial dynamics with direct implications on lung cancer progression and hence, deserve further exploration as therapeutic targets.
- Published
- 2013
- Full Text
- View/download PDF
27. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.
- Author
-
Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, and Wheeler DL
- Subjects
- Adenocarcinoma metabolism, Adenocarcinoma mortality, Adenocarcinoma pathology, Adenocarcinoma surgery, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor metabolism, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung surgery, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell surgery, Cell Nucleus metabolism, Disease-Free Survival, Female, Humans, Lung Neoplasms pathology, Lung Neoplasms surgery, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung mortality, ErbB Receptors metabolism, Lung Neoplasms metabolism, Lung Neoplasms mortality
- Abstract
Introduction: Nuclear EGFR (nEGFR) has been identified in various human tumor tissues, including cancers of the breast, ovary, oropharynx, and esophagus, and has predicted poor patient outcomes. We sought to determine if protein expression of nEGFR is prognostic in early stage non-small cell lung cancer (NSCLC)., Methods: Resected stages I and II NSCLC specimens were evaluated for nEGFR protein expression using immunohistochemistry (IHC). Cases with at least one replicate core containing ≥5% of tumor cells demonstrating strong dot-like nucleolar EGFR expression were scored as nEGFR positive., Results: Twenty-three (26.1% of the population) of 88 resected specimens stained positively for nEGFR. Nuclear EGFR protein expression was associated with higher disease stage (45.5% of stage II vs. 14.5% of stage I; p = 0.023), histology (41.7% in squamous cell carcinoma vs. 17.1% in adenocarcinoma; p = 0.028), shorter progression-free survival (PFS) (median PFS 8.7 months [95% CI 5.1-10.7 mo] for nEGFR positive vs. 14.5 months [95% CI 9.5-17.4 mo] for nEGFR negative; hazard ratio (HR) of 1.89 [95% CI 1.15-3.10]; p = 0.011), and shorter overall survival (OS) (median OS 14.1 months [95% CI 10.3-22.7 mo] for nEGFR positive vs. 23.4 months [95% CI 20.1-29.4 mo] for nEGFR negative; HR of 1.83 [95% CI 1.12-2.99]; p = 0.014)., Conclusions: Expression of nEGFR protein was associated with higher stage and squamous cell histology, and predicted shorter PFS and OS, in this patient cohort. Nuclear EGFR serves as a useful independent prognostic variable and as a potential therapeutic target in NSCLC., (Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
28. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.
- Author
-
Iida M, Brand TM, Campbell DA, Starr MM, Luthar N, Traynor AM, and Wheeler DL
- Subjects
- Allosteric Regulation, Apoptosis, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Cell Proliferation drug effects, Cetuximab, Drug Evaluation, Preclinical, Humans, MAP Kinase Signaling System, Mitogen-Activated Protein Kinases metabolism, Phosphorylation, Protein Processing, Post-Translational, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents pharmacology, Drug Resistance, Neoplasm, Heterocyclic Compounds, 3-Ring pharmacology, Proto-Oncogene Proteins c-akt antagonists & inhibitors
- Abstract
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for use in oncology. Despite clinical success the majority of patients do not respond to cetuximab and those who initially respond frequently acquire resistance. To understand how tumor cells acquire resistance to cetuximab we developed a model of resistance using the non-small cell lung cancer line NCI-H226. We found that cetuximab-resistant (Ctx (R) ) clones manifested strong activation of EGFR, PI3K/AKT and MAPK. To investigate the role of AKT signaling in cetuximab resistance we analyzed the activation of the AKT pathway effector molecules using a human AKT phospho-antibody array. Strong activation was observed in Ctx (R) clones for several key AKT substrates including c-jun, GSK3β, eIF4E, rpS6, IKKα, IRS-1 and Raf1. Inhibition of AKT signaling by siAKT1/2 or by the allosteric AKT inhibitor MK-2206 resulted in robust inhibition of cell proliferation in all Ctx (R) clones. Moreover, the combinational treatment of cetuximab and MK-2206 resulted in further decreases in proliferation than either drug alone. This combinatorial treatment resulted in decreased activity of both AKT and MAPK thus highlighting the importance of simultaneous pathway inhibition to maximally affect the growth of Ctx (R) cells. Collectively, our findings demonstrate that AKT activation is an important pathway in acquired resistance to cetuximab and suggests that combinatorial therapy directed at both the AKT and EGFR/MAPK pathways may be beneficial in this setting.
- Published
- 2013
- Full Text
- View/download PDF
29. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.
- Author
-
Iida M, Brand TM, Campbell DA, Li C, and Wheeler DL
- Subjects
- Antibodies, Monoclonal, Humanized, Cell Cycle Proteins metabolism, Cell Line, Tumor, Cetuximab, Humans, Nitric Oxide Synthase Type II metabolism, Phosphorylation, Trans-Activators metabolism, Antibodies, Monoclonal pharmacology, Carcinoma, Non-Small-Cell Lung metabolism, Cell Nucleus metabolism, Drug Resistance, Neoplasm, ErbB Receptors metabolism, Proto-Oncogene Proteins c-yes metabolism, src-Family Kinases metabolism
- Abstract
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR antibody that has been approved for use in oncology. Previously we investigated mechanisms of resistance to cetuximab using a model derived from the non-small cell lung cancer line NCI-H226. We demonstrated that cetuximab-resistant clones (Ctx(R)) had increased nuclear localization of the EGFR. This process was mediated by Src family kinases (SFKs), and nuclear EGFR had a role in resistance to cetuximab. To better understand SFK-mediated nuclear translocation of EGFR, we investigated which SFK member(s) controlled this process as well as the EGFR tyrosine residues that are involved. Analyses of mRNA and protein expression indicated upregulation of the SFK members Yes (v-Yes-1 yamaguchi sarcoma viral oncogene) and Lyn (v-yes-1 Yamaguchi sarcoma viral-related oncogene homolog) in all Ctx(R) clones. Further, immunoprecipitation analysis revealed that EGFR interacts with Yes and Lyn in Ctx(R) clones, but not in cetuximab-sensitive (Ctx(S)) parental cells. Using RNAi interference, we found that knockdown of either Yes or Lyn led to loss of EGFR translocation to the nucleus. Conversely, overexpression of Yes or Lyn in low nuclear EGFR-expressing Ctx(S) parental cells led to increased nuclear EGFR. Chromatin immunoprecipitation (ChIP) assays confirmed nuclear EGFR complexes associated with the promoter of the known EGFR target genes B-Myb and iNOS. Further, all Ctx(R) clones exhibited upregulation of B-Myb and iNOS at the mRNA and protein levels. siRNAs directed at Yes or Lyn led to decreased binding of EGFR complexes to the B-Myb and iNOS promoters based on ChIP analyses. SFKs have been shown to phosphorylate EGFR on tyrosines 845 and 1101 (Y845 and Y1101), and mutation of Y1101, but not Y845, impaired nuclear entry of the EGFR. Taken together, our findings demonstrate that Yes and Lyn phosphorylate EGFR at Y1101, which influences EGFR nuclear translocation in this model of cetuximab resistance.
- Published
- 2013
- Full Text
- View/download PDF
30. KRAS mutant colorectal tumors: past and present.
- Author
-
Brand TM and Wheeler DL
- Subjects
- Animals, Humans, Male, Antibodies, Monoclonal pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy, Proto-Oncogene Proteins genetics, Pyrimidines pharmacology, Thiazoles pharmacology, ras Proteins genetics
- Abstract
The treatment of metastatic colorectal cancer (mCRC) remains one of the largest hurdles in cancer therapeutics to date. The most advanced treatment option for mCRC patients are anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) that bind to and inhibit the activity of EGFR. While the use of anti-EGFR mABs has had great impact in the treatment of mCRC, it has now been widely accepted that mCRC tumors with a mutation in the small GTPase KRAS do not respond to these therapies. KRAS mutations allow for EGFR independent activation of various oncogenic signaling cascades. In attempts to inhibit KRAS mutant tumor growth, BRAF, MEK and farsenyltransferase inhibitors have been used, however, their clinical efficacy is still accruing in the setting of CRC. Recent data suggests that various other inhibitors, including inhibitors of Src family kinases (SFK) and hepatocyte growth factor receptor (MET), may have potential preclinical and clinical success in KRAS mutant tumors. Additionally, it is becoming increasingly clear that different KRAS missense mutations may have varied biological responses to cetuximab, suggesting that cetuximab may still be a potential therapeutic option in some KRAS mutant tumors. In this review, we highlight the importance for both improved multimodality approaches for treating KRAS mutant mCRC tumors and stratification of KRAS mutations in response to different treatment regimes in order to optimize the best possible care for mCRC patients.
- Published
- 2012
- Full Text
- View/download PDF
31. The nuclear epidermal growth factor receptor signaling network and its role in cancer.
- Author
-
Brand TM, Iida M, Li C, and Wheeler DL
- Subjects
- Humans, Cell Nucleus metabolism, ErbB Receptors metabolism, Neoplasms metabolism, Signal Transduction
- Abstract
The epidermal growth factor receptor (EGFR) is a member of the EGFR family of receptor tyrosine kinases (RTKs). EGFR activation via ligand binding results in signaling through various pathways ultimately resulting in cellular proliferation, survival, angiogenesis, invasion, and metastasis. Aberrant expression or activity of EGFR has been strongly linked to the etiology of several human epithelial cancers including but not limited to head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer, pancreatic cancer, and brain cancer. Thus intense efforts have been made to inhibit the activity of EGFR by designing antibodies against the ligand binding domains (cetuximab and panitumumab) or small molecules against the tyrosine kinase domain (erlotinib, gefitinib, and lapatinib). Although targeting membrane-bound EGFR has shown benefit, a new and emerging role for EGFR is now being elucidated. In this review we will summarize the current knowledge of the nuclear EGFR signaling network, including how it is trafficked to the nucleus, the functions it serves in the nucleus, and how these functions impact cancer progression, survival, and response to chemotherapeutics.
- Published
- 2011
32. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
- Author
-
Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, and Wheeler DL
- Subjects
- Animals, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Apoptosis drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Cetuximab, ErbB Receptors immunology, ErbB Receptors metabolism, Erlotinib Hydrochloride, Humans, Mice, Mice, Nude, Mitogen-Activated Protein Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism, RNA Interference, RNA, Small Interfering, Receptor, ErbB-2 metabolism, Xenograft Model Antitumor Assays, Antibodies, Monoclonal pharmacology, Drug Resistance, Neoplasm drug effects, ErbB Receptors antagonists & inhibitors, Quinazolines pharmacology
- Abstract
The epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase (RTK) and is recognized as a key mediator of tumorigenesis in many human tumors. Currently there are five EGFR inhibitors used in oncology, two monoclonal antibodies (panitumumab, and cetuximab) and three tyrosine kinase inhibitors (erlotinib, gefitinib, and lapatinib). Both strategies of EGFR inhibition have demonstrated clinical successes, however many tumors remain non-responsive or acquire resistance during therapy. To explore potential molecular mechanisms of acquired resistance to cetuximab we previously established a series of cetuximab-resistant clones by chronically exposing the NCI-H226 NSCLC cell line to escalating doses of cetuximab. Cetuximab-resistant clones exhibited a dramatic increase in steady-state expression of EGFR, HER2, and HER3 receptors as well as increased signaling through the MAPK and AKT pathways. RNAi studies demonstrated dependence of cetuximab-resistant clones on the EGFR signaling network. These findings prompted investigation on whether or not cells with acquired resistance to cetuximab would be sensitive to the EGFR targeted TKI erlotinib. In vitro, erlotinib was able to decrease signaling through the EGFR axis, decrease cellular proliferation, and induce apoptosis. To determine if erlotinib could have therapeutic benefit in vivo, we established cetuximab-resistant NCI-H226 mouse xenografts, and subsequently treated them with erlotinib. Mice harboring cetuximab-resistant tumors treated with erlotinib exhibited either a tumor regression or growth delay as compared to vehicle controls. Analysis of the erlotinib treated tumors demonstrated a decrease in cell proliferation and increase rates of apoptosis. The work presented herein suggests that 1) cells with acquired resistance to cetuximab maintain their dependence on EGFR and 2) tumors developing resistance to cetuximab can benefit from subsequent treatment with erlotinib, providing rationale for its use in the setting of cetuximab resistance.
- Published
- 2011
- Full Text
- View/download PDF
33. Mediastinal lymphadenopathy in patients undergoing cardiac transplant evaluation.
- Author
-
Pastis NJ Jr, Van Bakel AB, Brand TM, Ravenel JG, Gilbert GE, Silvestri GA, and Judson MA
- Subjects
- Adult, Aged, Female, Heart Failure complications, Heart Failure pathology, Humans, Lymphatic Diseases pathology, Male, Mediastinal Diseases pathology, Middle Aged, Retrospective Studies, Risk Factors, Sentinel Lymph Node Biopsy, Tomography, X-Ray Computed, Treatment Outcome, Heart Failure surgery, Heart Transplantation, Lymphatic Diseases etiology, Mediastinal Diseases etiology
- Abstract
Background: We evaluated the association between hemodynamic parameters of chronic congestive heart failure (CHF) and mediastinal lymphadenopathy (MLA) in heart transplantation (HT) candidates and the effect of HT on MLA. We also described the results of lymph node (LN) biopsies of MLA in the patients., Methods: Patients who underwent HT evaluation over an 8-year period and had chest CT scans were evaluated retrospectively. Data collected included LN sizes pre-HT and post-HT, echocardiographic measurements, radionuclide-derived ejection fraction, and right-sided heart catheterization hemodynamics. MLA was defined as LNs > 1 cm in smallest dimension., Results: Of 118 patients, 53 patients had MLA. MLA had weak statistically significant correlations with elevated mean pulmonary artery pressure (MPAP), mitral regurgitation (MR), tricuspid regurgitation (TR), right atrial pressure (RAP), and pulmonary capillary wedge pressure (PCWP). Thirty-six patients with MLA underwent HT, and nine of the 36 had post-HT chest CT scans. All nine patients showed a decrease in LN size post-HT (mean LN diameter pre-HT = 1.16 ± 0.137 cm, post-HT = 0.75 ± 0.32 cm). Seven of 53 patients with MLA underwent biopsies. Four had benign LNs, one had sarcoidosis, and two had lung cancer., Conclusions: MPAP, MR, TR, RAP, and PCWP had weak statistically significant correlations with MLA. HT led to regression of MLA in patients who underwent CT scans post-HT, implying that MLA is related to CHF. However, we also identified clinically important causes of MLA; therefore, biopsy should be considered if enlarged LNs fail to regress after maximal medical management of CHF.
- Published
- 2011
- Full Text
- View/download PDF
34. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
- Author
-
Brand TM, Iida M, and Wheeler DL
- Subjects
- Animals, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents therapeutic use, Cetuximab, Clinical Trials as Topic, Drug Resistance, Neoplasm, Humans, Antibodies, Monoclonal pharmacology, Antineoplastic Agents pharmacology, ErbB Receptors antagonists & inhibitors
- Abstract
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase belonging to the HER family of receptor tyrosine kinases. Receptor activation upon ligand binding leads to down stream activation of the PI3K/AKT, RAS/RAF/MEK/ERK and PLCγ/PKC pathways that influence cell proliferation, survival and the metastatic potential of tumor cells. Increased activation by gene amplification, protein overexpression or mutations of the EGFR has been identified as an etiological factor in a number of human epithelial cancers (e.g., NSCLC, CRC, glioblastoma and breast cancer). Therefore, targeting the EGFR has been intensely pursued as a cancer treatment strategy over the last two decades. To date, five EGFR inhibitors, including three small molecule tyrosine kinase inhibitors (TKIs) and two monoclonal antibodies have gained FDA approval for use in oncology. Both approaches to targeting the EGFR have shown clinical promise and the anti-EGFR antibody cetuximab is used to treat HNSCC and CRC. Despite clinical gains arising from use of cetuximab, both intrinsic resistance and the development of acquired resistance are now well recognized. In this review we focus on the biology of the EGFR, the role of EGFR in human cancer, the development of antibody-based anti-EGFR therapies and a summary of their clinical successes. Further, we provide an in depth discussion of described molecular mechanisms of resistance to cetuximab and potential strategies to circumvent this resistance.
- Published
- 2011
- Full Text
- View/download PDF
35. Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate.
- Author
-
Brand TM and Wheeler DL
- Subjects
- Breast Neoplasms genetics, Class I Phosphatidylinositol 3-Kinases, ErbB Receptors metabolism, Female, Humans, Phosphatidylinositol 3-Kinases metabolism, Prognosis, Breast Neoplasms drug therapy, Citrates therapeutic use, ErbB Receptors genetics, Phosphatidylinositol 3-Kinases genetics
- Published
- 2011
- Full Text
- View/download PDF
36. Enamel nail polish does not interfere with pulse oximetry among normoxic volunteers.
- Author
-
Brand TM, Brand ME, and Jay GD
- Subjects
- Adult, Color, Female, Fingers, Humans, Male, Middle Aged, Nails, Oximetry
- Abstract
Objective: To determine if enamel nail polish interferes with pulse oximetry., Design: Laboratory investigation., Participants: 12 healthy nonsmoking volunteers., Methods: Spectrophotometry was performed on polystyrene cuvettes painted with 3 uniform layers of nail polish enamel in triplicate. Absorbances were compared at 660 and 940 nm for 10 colors across the visible spectrum and documented by the Institute of Electrical and Electronic Engineers color code against Pantone matches on a color scanner. Colors were then selected that had the greatest A660-A940 difference and pulse oximetry (Nellcor N-209A. Pleasanton , CA) was performed on nails painted with these colors on 12 subjects using an unpainted digit as a control., Results: When tested by the oximeter, there were no SpO2 differences detected between nail polish colors, nor were there any differences between the painted and the unpainted control digits across subjects (F = 0.51, ANOVA; p = 0.67). Blue (B), green (G), and lime green (G') possessed the largest A660-A940 difference and potentially could interfere with pulse oximetry but did not do so in the clinical model., Conclusion: Enamel finger nail polish pigments do not interfere with pulse oximetry as previously reported, the A660-A940 difference must be greater than 1.88 +/- 0.23 SD AU in order to affect pulse oximetry.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.